The typical investor has caved in to negativity. Many have sold off big percentages of their stock, fund and ETF positions.
China's government is more concerned about stopping the spread of Covid-19 than spurring the economy back to life.
It wouldn't be surprising if the market gave some of it back early in the week, only to rally again later in the week.
Similar to biotech, the small adtech space has been hammered in recent quarters and has likely hit oversold territory.
These recently downgraded names are displaying both quantitative and technical deterioration.
Remember, behind every bear market a bull is waiting. Here's how to survive and thrive while stocks growl.
The action Friday is a good start, but it requires much more work before it can be trusted.
Selloffs like what we've experienced in 2022 bring with them more favorable valuations, and higher dividend yields for quality names.
The shares have been cut in half in just short of five months.
Could I be wrong about the capitulation low? Indeed. Here's how to tell if I am off, and what to do if I'm right.